A health economic model to assess the cost-effectiveness of OPTIFAST for the treatment of obesity in the United States (vol 21, pg 835, 2018)

被引：0
|
作者：
Nuijten, M. [1 ]
Marczewska, A. [1 ]
Torres, Araujo K. [1 ]
Rasouli, B. [1 ]
Perugini, M. [1 ]
机构：
[1] Ars Accessus Med, Amsterdam, Netherlands
来源：
JOURNAL OF MEDICAL ECONOMICS | 2018年 / 21卷 / 09期
关键词：
D O I：
10.1080/13696998.2018.1484647
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：845 / 845
页数：1
相关论文
共 50 条
  • [31] Cost-Effectiveness and Budget Impact of Lumacaftor/Ivacaftor in the Treatment of Cystic Fibrosis (vol 24, pg 987, 2018)
    Vadagam, P.
    Kamal, K. M.
    Covvey, J. R.
    Giannetti, V
    Mukherjee, K.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2019, 25 (02): : 285 - 286
  • [32] Cost-Effectiveness in Adult Spinal Deformity Surgery (vol 83, pg 597, 2018)
    Arutyunyan, Grigoriy G.
    NEUROSURGERY, 2019, 84 (03) : 815 - 815
  • [33] Lessons from cost-effectiveness research for United States public health policy
    Grosse, Scott D.
    Teutsch, Steven M.
    Haddix, Anne C.
    ANNUAL REVIEW OF PUBLIC HEALTH, 2007, 28 : 365 - 391
  • [34] Cost-effectiveness Analysis and Geographic Variation in Health Care Costs in the United States
    Predmore, Zachary
    MEDICAL DECISION MAKING, 2019, 39 (01) : 3 - 4
  • [35] Cost effectiveness of contraceptives in the United States (vol 79, pg 5, 2009)
    Trussell, James
    Lalla, Anjana M.
    Doan, Quan V.
    Reyes, Eileen
    Pinto, Lionel
    Gricar, Joseph
    CONTRACEPTION, 2009, 80 (02) : 229 - 230
  • [36] Cost-Effectiveness Model Comparing Olanzapine and Other Oral Atypical Antipsychotics in the Treatment of Schizophrenia in the United States
    Svanum, Ascher H.
    Furiak, N. M.
    Klein, R. W.
    Smolen, L. J.
    Lawson, A. H.
    Conley, R. R.
    JOURNAL OF MENTAL HEALTH POLICY AND ECONOMICS, 2009, 12 : S3 - S4
  • [37] A dynamic model and cost-effectiveness on screening coverage and treatment of syphilis included MSM population in the United States
    Huang, Huansen
    Zhang, Jinhui
    Zhang, Zhiheng
    Li, Shuang
    Zhou, Quan
    Li, Yong
    ADVANCES IN CONTINUOUS AND DISCRETE MODELS, 2024, 2024 (01):
  • [38] Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States
    Furiak N.M.
    Ascher-Svanum H.
    Klein R.W.
    Smolen L.J.
    Lawson A.H.
    Conley R.R.
    Culler S.D.
    Cost Effectiveness and Resource Allocation, 7 (1)
  • [39] The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States
    Messali, Andrew
    Hay, Joel W.
    Villacorta, Reginald
    NEURO-ONCOLOGY, 2013, 15 (11) : 1532 - 1542
  • [40] Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States
    Jia, Xiaoying
    Zhao, Yang
    Carrico, Justin
    Brodtkorb, Thor-Henrik
    Mendelsohn, Alan M.
    Lowry, Simon
    Feldman, Steve
    Wu, Jashin J.
    Armstrong, April W.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (02) : 740 - 748
12345